Skip to main content
SpringerLink
Log in

Myocarditis

  • Chapter
  • First Online:
FDG-PET/CT and PET/MR in Cardiovascular Diseases

  • 304 Accesses

Abstract

Myocarditis comprises a group of diseases characterized by inflammation of the myocardium. It is associated with a broad range of clinical presentations, from asymptomatic to cardiogenic shock and malignant arrhythmias. The true incidence of myocarditis is not precisely known due to heterogeneity of clinical presentation and because endomyocardial biopsy, the gold standard for the diagnosis of myocarditis, is not always performed. Positron emission tomography (PET) has become an important tool for the evaluation of patients with granulomatous myocarditis (sarcoidosis). However, for other types of myocarditis such as lymphocytic myocarditis, giant cell myocarditis, and eosinophilic cardiomyopathy, the role of PET remains poorly investigated. In this chapter, the epidemiology, clinical presentation, classification, and treatment options of myocarditis, in addition to the current diagnostic strategies and the role of cardiac magnetic resonance imaging (CMR) and positron emission tomography (PET) will be reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J. 2013;34(33):2636–48, 2648a–2648d.

    Article  PubMed  Google Scholar 

  2. Trachtenberg BH, Hare JM. Inflammatory cardiomyopathic syndromes. Circ Res. 2017;121(7):803–18.

    Article  CAS  PubMed  Google Scholar 

  3. Fung E, Fong MW, Correa AJ, Yoon AJ, Grazette LP. Fulminant eosinophilic myocarditis following ICD implantation in a patient with undisclosed nickel allergy. Int J Cardiol. 2015;203:1018–9.

    Article  PubMed  Google Scholar 

  4. Global Burden of Disease Study C. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386(9995):743–800.

    Article  Google Scholar 

  5. Tschope C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021;18(3):169–93.

    Article  PubMed  Google Scholar 

  6. McCarthy RE 3rd, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med. 2000;342(10):690–5.

    Article  PubMed  Google Scholar 

  7. Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003;107(6):857–63.

    Article  PubMed  Google Scholar 

  8. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter giant cell myocarditis study group investigators. N Engl J Med. 1997;336(26):1860–6.

    Article  PubMed  Google Scholar 

  9. Kandolin R, Lehtonen J, Salmenkivi K, Räisänen-Sokolowski A, Lommi J, Kupari M. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail. 2013;6(1):15–22.

    Article  CAS  PubMed  Google Scholar 

  10. Ekstrom K, Lehtonen J, Kandolin R, Raisanen-Sokolowski A, Salmenkivi K, Kupari M. Incidence, risk factors, and outcome of life-threatening ventricular arrhythmias in giant cell myocarditis. Circ Arrhythm Electrophysiol. 2016;9(12):e004559. https://www.ncbi.nlm.nih.gov/pubmed/27913400.

    Article  PubMed  Google Scholar 

  11. Ekstrom K, Lehtonen J, Kandolin R, Raisanen-Sokolowski A, Salmenkivi K, Kupari M. Long-term outcome and its predictors in giant cell myocarditis. Eur J Heart Fail. 2016;18(12):1452–8.

    Article  PubMed  Google Scholar 

  12. Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis-state of the art review. Cardiovasc Diagn Ther. 2016;6(1):50–63.

    PubMed  PubMed Central  Google Scholar 

  13. Rybicki BA, Sinha R, Iyengar S, Gray-McGuire C, Elston RC, Iannuzzi MC, et al. Genetic linkage analysis of sarcoidosis phenotypes: the sarcoidosis genetic analysis (SAGA) study. Genes Immun. 2007;8(5):379–86.

    Article  CAS  PubMed  Google Scholar 

  14. Spagnolo P, Schwartz DA. Genetic predisposition to sarcoidosis: another brick in the wall. Eur Respir J. 2013;41(4):778–80.

    Article  CAS  PubMed  Google Scholar 

  15. Nery PB, Beanlands RS, Nair GM, Green M, Yang J, McArdle BA, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol. 2014;25(8):875–81.

    Article  PubMed  Google Scholar 

  16. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol. 2011;4(3):303–9.

    Article  PubMed  Google Scholar 

  17. Nery PB, Mc Ardle BA, Redpath CJ, Leung E, Lemery R, Dekemp R, et al. Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2014;37(3):364–74.

    Article  PubMed  Google Scholar 

  18. Philips B, Madhavan S, James CA, te Riele AS, Murray B, Tichnell C, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy and cardiac sarcoidosis: distinguishing features when the diagnosis is unclear. Circ Arrhythm Electrophysiol. 2014;7(2):230–6.

    Article  PubMed  Google Scholar 

  19. Birnie DH, Nery PB, Ha AC, Beanlands RS. Cardiac Sarcoidosis. J Am Coll Cardiol. 2016;68(4):411–21.

    Article  PubMed  Google Scholar 

  20. Martineau P, Pelletier-Galarneau M, Juneau D, Leung E, Birnie D, Beanlands RSB. Molecular imaging of cardiac sarcoidosis. Curr Cardiovasc Imaging Rep. 2018;11(3):6–17.

    Article  Google Scholar 

  21. Birnie DH, Sauer WH, Judson MA. Consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart. 2016;102(6):411–4.

    Article  CAS  PubMed  Google Scholar 

  22. Ogbogu PU, Rosing DR, Horne MK 3rd. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):457–75.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Antonopoulos AS, Azzu A, Androulakis E, Tanking C, Papagkikas P, Mohiaddin RH. Eosinophilic heart disease: diagnostic and prognostic assessment by cardiac magnetic resonance. Eur Heart J Cardiovasc Imaging. 2021;22(11):1273–84. https://www.ncbi.nlm.nih.gov/pubmed/33432319.

    Article  PubMed  Google Scholar 

  24. Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the heart failure Association of the European Society of cardiology. Eur Heart J. 2007;28(24):3076–93.

    Article  PubMed  Google Scholar 

  25. Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis. experimental and clinical correlates. Circulation. 1997;95(1):163–8.

    Article  CAS  PubMed  Google Scholar 

  26. Giraldeau G. The right way to the left ventricle: a better approach to endomyocardial biopsy? Can J Cardiol. 2018;34(10):1247–9.

    Article  PubMed  Google Scholar 

  27. Jeserich M, Konstantinides S, Pavlik G, Bode C, Geibel A. Non-invasive imaging in the diagnosis of acute viral myocarditis. Clin Res Cardiol. 2009;98(12):753–63.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Fernández-Jiménez R, Sánchez-González J, Aguero J, Del Trigo M, Galán-Arriola C, Fuster V, et al. Fast T2 gradient-spin-echo (T2-Gra SE) mapping for myocardial edema quantification: first in vivo validation in a porcine model of ischemia/reperfusion. J Cardiovasc Magn Reson. 2015;17:92.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Abdel-Aty H, Boyé P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45(11):1815–22.

    Article  PubMed  Google Scholar 

  30. Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):3158–76.

    Article  PubMed  Google Scholar 

  31. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53(17):1475–87.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Cummings KW, Bhalla S, Javidan-Nejad C, Bierhals AJ, Gutierrez FR, Woodard PK. A pattern-based approach to assessment of delayed enhancement in nonischemic cardiomyopathy at MR imaging. Radiographics. 2009;29(1):89–103.

    Article  PubMed  Google Scholar 

  33. Kuchynka P, Palecek T, Masek M, Cerny V, Lambert L, Vitkova I, et al. Current diagnostic and therapeutic aspects of eosinophilic myocarditis. Biomed Res Int. 2016;2016:2829583.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Yang F, Wang J, Li W, Xu Y, Wan K, Zeng R, et al. The prognostic value of late gadolinium enhancement in myocarditis and clinically suspected myocarditis: systematic review and meta-analysis. Eur Radiol. 2020;30(5):2616–26.

    Article  CAS  PubMed  Google Scholar 

  35. Blissett S, Chocron Y, Kovacina B, Afilalo J. Diagnostic and prognostic value of cardiac magnetic resonance in acute myocarditis: a systematic review and meta-analysis. Int J Cardiovasc Imaging. 2019;35(12):2221–9.

    Article  PubMed  Google Scholar 

  36. Luetkens JA, Faron A, Isaak A, Dabir D, Kuetting D, Feisst A, et al. Comparison of original and 2018 Lake Louise criteria for diagnosis of acute myocarditis: results of a validation cohort. Radiol Cardiothorac Imaging. 2019;1(3):e190010.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Gutberlet M, Lücke C. Original versus 2018 Lake Louise criteria for acute myocarditis diagnosis: old versus new. Radiol Cardiothorac Imaging. 2019;1(3):e190150.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Nensa F, Poeppel TD, Krings P, Schlosser T. Multiparametric assessment of myocarditis using simultaneous positron emission tomography/magnetic resonance imaging. Eur Heart J. 2014;35(32):2173.

    Article  PubMed  Google Scholar 

  39. Gesa v O, Fabien H, Nicolas L, Karl-Ludwig L, Markus S, Tareq I. Detection of acute inflammatory myocarditis in Epstein Barr virus infection using hybrid 18F-Fluoro-Deoxyglucose–positron emission tomography/magnetic resonance imaging. Circulation. 2014;130(11):925–6.

    Article  Google Scholar 

  40. Aleksova N, Juneau D, Dick A, Green M, Birnie D, Beanlands RS, et al. Role of 18F-Fluorodeoxyglucose/positron emission tomography imaging to demonstrate resolution of acute myocarditis. Can J Cardiol. 2017;33(2):293.e3–5.

    Article  Google Scholar 

  41. Takano H, Nakagawa K, Ishio N, Daimon M, Daimon M, Kobayashi Y, et al. Active myocarditis in a patient with chronic active Epstein-Barr virus infection. Int J Cardiol. 2008;130(1):e11–3.

    Article  PubMed  Google Scholar 

  42. Abgral R, Dweck MR, Trivieri MG, Robson PM, Karakatsanis N, Mani V, et al. Clinical utility of combined FDG-PET/MR to assess myocardial disease. JACC Cardiovasc Imaging. 2017;10(5):594–7.

    Article  PubMed  Google Scholar 

  43. Simon R, Perel-Winkler A, Bokhari S, Fazlollahi L, Nickerson K. Myocarditis in Giant cell arteritis diagnosed with fluorine 18–labeled Fluorodeoxyglucose positron emission tomography–computed tomography: case report and review of the literature. J Clin Rheumatol. 2020;26(2):e37.

    Article  PubMed  Google Scholar 

  44. Gracia E, Monach P, Shih J. Monitoring of disease activity in eosinophilic myocarditis via pet scans. J Am Coll Cardiol. 2020;75(11 Supplement 1):2559.

    Article  Google Scholar 

  45. Langwieser N, von Olshausen G, Rischpler C, Ibrahim T. Confirmation of diagnosis and graduation of inflammatory activity of Loeffler endocarditis by hybrid positron emission tomography/magnetic resonance imaging. Eur Heart J. 2014;35(36):2496.

    Article  PubMed  Google Scholar 

  46. Moriwaki K, Dohi K, Omori T, Tanimura M, Sugiura E, Nakamori S, et al. A survival case of fulminant right-side dominant eosinophilic myocarditis. Int Heart J. 2017;58(3):459–62.

    Article  PubMed  Google Scholar 

  47. Lamacie MM, Aws A, Vidhya N, Ellamae S, David B, Beanlands Rob SB, et al. Serial 18F-Fluorodeoxyglucose positron emission tomography imaging in a patient with Giant cell myocarditis. Circ Cardiovasc Imaging. 2020;13(2):e009940.

    Article  PubMed  Google Scholar 

  48. Tanimura M, Dohi K, Imanaka-Yoshida K, Omori T, Moriwaki K, Nakamori S, et al. Fulminant myocarditis with prolonged active lymphocytic infiltration after hemodynamic recovery. Int Heart J. 2017;58(2):294–7.

    Article  PubMed  Google Scholar 

  49. Palmisano A, Vignale D, Peretto G, Busnardo E, Calcagno C, Campochiaro C, et al. Hybrid FDG-PET/MR or FDG-PET/CT to detect disease activity in patients with persisting arrhythmias after myocarditis. JACC Cardiovasc Imaging. 2020;14(1):288–92.

    Article  PubMed  Google Scholar 

  50. Pelletier-Galarneau M, Ruddy TD. PET/CT for diagnosis and management of large-vessel vasculitis. Curr Cardiol Rep. 2019;21(5):34.

    Article  PubMed  Google Scholar 

  51. Ozawa K, Funabashi N, Daimon M, Takaoka H, Takano H, Uehara M, et al. Determination of optimum periods between onset of suspected acute myocarditis and 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of inflammatory left ventricular myocardium. Int J Cardiol. 2013;169(3):196–200.

    Article  PubMed  Google Scholar 

  52. Chen W, Jeudy J. Assessment of myocarditis: cardiac MR, PET/CT, or PET/MR? Curr Cardiol Rep. 2019;21(8):76.

    Article  PubMed  Google Scholar 

  53. Nensa F, Kloth J, Tezgah E, Poeppel TD, Heusch P, Goebel J, et al. Feasibility of FDG-PET in myocarditis: comparison to CMR using integrated PET/MRI. J Nucl Cardiol. 2018;25(3):785–94.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Montreal Heart Institute, Montréal, QC, Canada

    Geneviève Giraldeau, Julia Cadrin-Tourigny & Matthieu Pelletier-Galarneau

  2. BC Cancer, Vancouver, BC, Canada

    Patrick Martineau

Authors
  1. Geneviève Giraldeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia Cadrin-Tourigny
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick Martineau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matthieu Pelletier-Galarneau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthieu Pelletier-Galarneau .

Editor information

Editors and Affiliations

  1. Montreal Heart Institute, Montréal, QC, Canada

    Matthieu Pelletier-Galarneau

  2. BC Cancer Agency, Vancouver, BC, Canada

    Patrick Martineau

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Giraldeau, G., Cadrin-Tourigny, J., Martineau, P., Pelletier-Galarneau, M. (2022). Myocarditis. In: Pelletier-Galarneau, M., Martineau, P. (eds) FDG-PET/CT and PET/MR in Cardiovascular Diseases. Springer, Cham. https://doi.org/10.1007/978-3-031-09807-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-09807-9_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-09806-2

  • Online ISBN: 978-3-031-09807-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation